Halo Therapeutics is a startup that focuses on the development of pan-coronavirus antivirals. Their primary goal is to address the urgent medical need for safe and effective treatments that can be self-administered by COVID-19 patients at home. The company's proprietary free fatty acid formula is designed to render the SARS-CoV-2 spike protein non-infectious, thereby inhibiting the virus's ability to cause disease.

The company operates in the pharmaceutical and healthcare market, specifically targeting the ongoing global pandemic. Their business model revolves around the development and commercialization of their novel antiviral therapeutics. They generate revenue through the sale of these therapeutics once they have been approved for use.

Halo Therapeutics is led by a team of scientists with a strong track record in drug discovery. They leverage their expertise in structural biology, virology, and computational chemistry to advance their pipeline of antiviral therapeutics.

The company is backed by a mix of institutional and private investors, including the Development Bank of Wales, the KBA group, and Science Angels Syndicate. These investors provide the necessary financial support for the company to continue its research and development efforts.

In summary, Halo Therapeutics is a promising startup in the pharmaceutical industry, with a focus on developing effective treatments for COVID-19 and other coronaviruses. Their innovative approach to antiviral therapy could potentially have a significant impact on global public health.

Keywords: Halo Therapeutics, pan-coronavirus antivirals, COVID-19, SARS-CoV-2, free fatty acid formula, pharmaceutical industry, healthcare market, drug discovery, institutional investors, private investors.